Nucleome Therapeutics
Drug Discovery
- [email protected]
- Website
- https://nucleome.com/
- Membership category
- Corporate
Inventa, Botley Road, Oxford, OX2 0HA, United Kingdom
Nucleome Therapeutics at a glance
About Nucleome Therapeutics
Nucleome is using breakthrough genomics technologies to discover first-in-class antibody therapeutics for inflammatory diseases. The approach is based solely on human disease genetics and biology. Nucleome is able, for the first time, to reveal molecular mechanisms of disease and select drug targets using human genetic variants in the non-coding genome that alter gene expression. The Company’s proprietary 3D genomics combines lab and machine learning technologies which can be applied to any set of disease-associated variants.
Lead program NTP464 is an antibody that activates an inflammation checkpoint. NTP464 stimulates natural cellular processes of inflammation resolution, a new principle in the treatment of inflammation with huge potential patient benefit. Other multiple targets based on the genetics of inflammatory diseases are in discovery.
Nucleome is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.
